Publications by authors named "Deborah Toppmeyer"

Claim this Profile
P
Preoperative Radiation Boost Results in Low Rates of Re-excision and Reduced Locoregional Treatment Time in Breast Cancer Patients.
Molly A Chakraborty, Zohaib K Sherwani, Lakshmi Rekha Narra, Zeinab Abou Yehia, Nisha Ohri, Deborah L Toppmeyer

Ann Surg Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: "Preoperative Radiation Boost in Early Stage Breast Cancer: Effect on Re-excision and Complication Rates," by Sanli, Deniz et al.
Molly Chakraborty, Zohaib Sherwani, Lakshmi Rekha Narra, Zeinab Abou Yehia, Ohri Nisha, Deborah Toppmeyer

Ann Surg Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Preoperative Radiation Boost on Oncotype DX Result in a Phase II Clinical Trial.
Firas Eladoumikdachi, Molly A Chakraborty, Nisha Ohri, Maria Kowzun, Shicha Kumar, Deborah Toppmeyer

Ann Surg Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Remote Tailored Risk Communication and Navigation for Hereditary Genetic Risk Assessment Uptake: Economic Evaluation From the Genetic Risk Assessment for Cancer Education and Empowerment Trial.
Elizabeth A Handorf, Jean A McDougall, Emily Heidt, Jinghua An, Scott T Walters, Deborah L Toppmeyer

JCO Oncol Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Results of the Primary Outcome of a Phase 2 Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Patients With Breast Cancer.
Zeinab Abou Yehia, Zohaib Sherwani, Molly Chakraborty, Nisha Ohri, Alison Grann, Deborah Toppmeyer

Int J Radiat Oncol Biol Phys· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian Suppression: Early Menopause, Late Effects.
Chaya Goldberg, Megan R Greenberg, Alexandra Noveihed, Laila Agrawal, Coral Omene, Deborah Toppmeyer

Curr Oncol Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up.
Jinghua An, Jean McDougall, Yong Lin, Shou-En Lu, Scott T Walters, Deborah Toppmeyer

JNCI Cancer Spectr· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment.
Sophia Gandarillas, Elizabeth Schoenberg Newland, Deborah Toppmeyer, Ryan Stephenson, Lisa Denzin

Front Med (Lausanne)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Clinical and Cosmetic Outcomes of Once-Daily Accelerated Partial Breast Irradiation in Early Breast Cancer.
Ritesh Kumar, Kelly Krupa, Zeinab Abou Yehia, Shicha Kumar, Lindsay Potdevin, Deborah Toppmeyer

Adv Radiat Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting and implementing breast cancer follow-up in primary care: protocol for a mixed methods hybrid type 1 effectiveness-implementation cluster randomized study.
Sarah J Fadem, Benjamin F Crabtree, Denalee M O'Malley, Lisa Mikesell, Jeanne M Ferrante, Deborah L Toppmeyer

BMC Prim Care· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Mediators of Intervention Effects Within a Randomized Controlled Trial to Motivate Cancer Genetic Risk Assessment Among Breast and Ovarian Cancer Survivors.
Jinghua An, Shou-En Lu, Jean McDougall, Scott T Walters, Yong Lin, Deborah Toppmeyer

Ann Behav Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of PARP inhibitors in breast cancer.
Karan Pandya, Alyssa Scher, Coral Omene, Shridar Ganesan, Shicha Kumar, Deborah L Toppmeyer

Breast Cancer Res Treat· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
Anita Y Kinney, Scott T Walters, Yong Lin, Shou-En Lu, Arreum Kim, Deborah L Toppmeyer

J Clin Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer.
Geena Chacko, Srigowri Kota, Shicha Kumar, Nisha Ohri, Coral Omene, Deborah L Toppmeyer

Anticancer Drugs· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
Sherene Loi, Roberto Salgado, Peter Schmid, Javier Cortes, David W Cescon, Deborah L Toppmeyer

JCO Precis Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial.
Circe Gray Le Compte, Shou-En Lu, Julianne Ani, Jean McDougall, Scott T Walters, Deborah Toppmeyer

Health Psychol Behav Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker.
Sadaf Qureshi, Nancy Chan, Mridula George, Shridar Ganesan, Deborah Toppmeyer

Biomark Insights· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.
Mridula A George, Sadaf Qureshi, Coral Omene, Deborah L Toppmeyer, Shridar Ganesan

Front Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center.
Mansi R Shah, Imraan Jan, Jeremy Johns, Kuldip Singh, Pallavi Kumar, Deborah L Toppmeyer

Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.
Elan Gorshein, Kant Matsuda, Gregory Riedlinger, Levi Sokol, Lorna Rodriguez-Rodriguez, Deborah L Toppmeyer

Case Rep Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
Mark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, William T Barry, Eric P Winer, Deborah Toppmeyer

J Natl Cancer Inst· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
Kathy S Albain, Robert J Gray, Della F Makower, Amir Faghih, Daniel F Hayes, Deborah L Toppmeyer

J Natl Cancer Inst· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of Hypofractionated Whole-Breast Radiotherapy With Concurrent Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy.
Mutlay Sayan, Irina Vergalasova, Sachin Jhawar, Shicha Kumar, Mridula George, Deborah Toppmeyer

Clin Breast Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Deborah L Toppmeyer, Michael F Press

Cancer Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial.
Matthew M Poppe, Zeinab A Yehia, Christopher Baker, Sharad Goyal, Deborah Toppmeyer

Int J Radiat Oncol Biol Phys· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis